PUBLISHER: Grand View Research | PRODUCT CODE: 2151938
PUBLISHER: Grand View Research | PRODUCT CODE: 2151938
The global hemorrhagic stroke treatment devices market size was valued at USD 1.9 billion in 2025 and is projected to grow from USD 2.0 billion in 2026 to USD 3.1 billion by 2033, at a CAGR of 6.2% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 43.8% in 2025. The industry is driven by the rising incidence of intracerebral hemorrhage and cerebral aneurysms, particularly among aging populations and patients with hypertension.
The rising incidence of intracerebral hemorrhage and cerebral aneurysms increases the number of patients requiring urgent medical intervention, directly boosting demand for hemorrhagic stroke treatment devices. As more cases are diagnosed, healthcare providers adopt advanced endovascular and minimally invasive technologies to improve outcomes, which in turn drives market growth and encourages continued innovation and investment in treatment solutions.
Multiple countries across Europe continue to report a significant hemorrhagic stroke burden, contributing to anticipated market expansion.
According to the Global Stroke Fact Sheet 2025 published by the World Stroke Organization, more than 12 million new stroke cases occur annually, and nearly one in four people worldwide will experience a stroke during their lifetime. The report indicates that intracerebral hemorrhage (ICH) accounts for 28.8% and subarachnoid hemorrhage (SAH) for 5.8% of all incident strokes, underscoring the substantial hemorrhagic stroke burden. The growing prevalence of this disease is expected to be a key driver of market growth during the forecast period.
According to data published by the American Heart Association in February 2022, hemorrhagic strokes account for approximately 10% of the nearly 800,000 stroke cases reported annually in the U.S., and they are associated with a higher mortality rate compared to other stroke types. This considerable disease burden is anticipated to drive demand for hemorrhagic stroke treatment devices.
The increasing focus on minimally invasive treatment strategies, including early minimally invasive evacuation of intracerebral hemorrhage (ICH) and endoscopic hematoma removal, is expected to be a key driver of market growth over the forecast period. Ongoing clinical trials are supporting the development of technologies that improve procedural safety and clinical outcomes. For example, in April 2024, NICO Corporation reported positive results from the ENRICH (Early MiNimally-invasive Removal of ICH) clinical trial, showing that early minimally invasive parafascicular surgery (MIPS) using its BrainPath and Myriad systems was safe and demonstrated superior outcomes compared with guideline-based medical management alone, the current standard of care for ICH.
Global Hemorrhagic Stroke Treatment Devices Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis on the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global hemorrhagic stroke treatment devices market report on the basis of treatment type, end-use, and region: